Clinical Report: Analytical Champions: Robert Wethman

Overview

Robert Wethman describes analytical science as both a foundation for reliable manufacturing methods and an increasingly strategic contributor to development timelines and outcomes. He identifies growing molecular, modality, and process complexity as a source of analytical bottlenecks, and discusses spectroscopy as a way to increase analytical speed when appropriately selected and implemented.

Background

Analytical science supports pharmaceutical manufacturing through robust and reliable measurement methods. Wethman notes that modern development faces simultaneous increases in the complexity of molecules, modalities, and manufacturing processes, alongside compressed timelines. These conditions make alignment between analytical strategy and development and manufacturing strategy important. Real-time spectroscopy may provide value across a product lifecycle, but its adoption requires evaluation of cost, operational impact, and support needs.

Data Highlights

The source provides no numerical trial or outcome data. Wethman reports that at-line spectroscopy has been used at Bristol Myers Squibb-owned and CDMO sites, while broader routine implementation of real-time spectroscopy remains limited.

Key Findings

• Wethman characterizes analytical science as foundational to manufacturing and increasingly strategic because technology selection, deployment timing, and integration can affect development timelines and outcomes.
• He identifies the concurrent growth in molecule, modality, and manufacturing-process complexity, together with compressed timelines, as a major source of analytical bottlenecks.
• He says spectroscopy can increase the speed of analysis and may help address complexity when appropriate.
• Implementation of real-time spectroscopy requires early knowledge sharing, shared goals and understanding of limitations, and planning for long-term support and operational impact.
• Wethman reports that at-line spectroscopy has been used at BMS-owned and CDMO sites as a practical bridge while evaluating the need for full real-time monitoring.
• He says routine adoption remains limited, noting that many CMOs and CDMOs have not yet invested sufficiently in real-time spectroscopy equipment and expertise.

Clinical Implications

Wethman’s account indicates that teams considering real-time spectroscopy should assess cost and benefit at each development stage and involve operations early to understand implementation and support requirements. At-line applications are described as a practical option for realizing immediate benefits while assessing whether full real-time monitoring is needed.

Conclusion

Wethman presents analytical strategy, operational collaboration, and implementation planning as central considerations as pharmaceutical processes and modalities become more complex. He describes at-line spectroscopy as an established bridge, while routine real-time monitoring remains a work in progress.

Related Resources & Content

1. The Analytical Scientist, 2026 -- Frontline Pharma: Robert Wethman
2. The Analytical Scientist, 2015 -- Beyond the Champions League
3. The Medicine Maker, 2026 -- Analytical Champions: Tao Chen
4. The Analytical Scientist — One Analytical Conundrum at a Time
5. Q2(R2) Validation of Analytical Procedures | FDA
6. Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application | FDA
7. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer | FDA